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Abstract 
 
          Apolipoprotein (apo) E4 is a risk factor for Alzheimer’s disease, compared to wild-type 
apoE3.  The mechanism(s) is unknown.  One possibility, demonstrated in peripheral tissue cell 
lines, is that apoE stimulates nitric oxide synthase (NOS) via a receptor-dependent signalling 
pathway and that apoE4 generates inappropriate amounts of NO compared to apoE3.  Prior to 
biochemical investigations, we have quantified the expression of several candidate receptor 
genes, including low-density lipoprotein (LDL)-receptor family members and scavenger 
receptor class B, types I and II (SR-BI/II), as well as the three NOS isoenzymes and protein 
kinase B (Akt), in 38 human cell lines, of which 12 derive from brain.  Expression of apoE 
receptor 2 (apoER2), a known signalling receptor in brain, was readily detected in SH-SY-5Y 
and CCF-STTG1 cells, common models of neurons and astrocytes, respectively, and was 
highest in H4 neuroglioma and IMR-32 neuroblastoma cells.  Transcripts of the other 
lipoprotein receptors were widely, but variably, distributed across the different cell types.  Of 
particular note was the predominant expression of SR-BII over SR-BI in many of the brain-
derived cells.  As the C-terminus of SR-BII, like apoER2, contains potential SH3 signalling 
motifs, we suggest that in brain SR-BII functions as a signal transducer receptor.  
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1. Introduction 
 
Alzheimer’s disease (AD) is the most common neurodegenerative disease and accounts 
for approximately two-thirds of all cases of dementia [1]. Genetic linkage analysis has identified 
highly penetrant missense mutations in three genes in familial forms of AD, which directly 
affect disease pathology hallmarks: the amyloid precursor protein (APP) gene on chromosome 
21, presenilin-1 (PS-1) on chromosome 14 and presenilin-2 (PS-2) on chromosome 1 [2-4].  
Despite this, 90-95% of AD cases are late-onset, occurring sporadically with no observable 
mutation in the APP or presenilin genes [5,6].  Genes involved in sporadic AD most likely affect 
disease progression indirectly by modulating one or more metabolic functions in brain relating 
to normal biosynthesis and homeostasis. 
Over 10 years ago, the ε4 allele of apolipoprotein E (apoE) was identified as a key 
susceptibility gene in development of late-onset AD [7,8].  Plasma apoE helps regulate 
cholesterol metabolism by high-affinity receptor binding, which initiates uptake of lipoprotein 
particles for lysosomal degradation [9].  There are three common apoE alleles, ε2, ε3 and ε4, 
which arise from single nucleotide polymorphisms and have frequencies of about 8, 77 and 15 
%, respectively, in Caucasian populations [9].  Each isoform has physiologically distinct 
receptor binding affinities, reflecting amino acid substitutions, R158C (apoE2) and C112R 
(apoE4) [9-11].  Brain has the second highest level of apoE mRNA, most being synthesized by 
astrocytes and microglia [12].   ApoE fulfills several functions in brain, all mediated via 
receptor-binding: maintenance of cholesterol homeostasis; a targeting protein for local 
cholesterol redistribution within tissue undergoing repair or re-modelling; an emerging role in 
developmental processes; and synapse formation [13,14].. 
The well-established pathological hallmarks of AD are the deposition of β-amyloid (Aβ) 
in plaques and the accumulation of neurofibrillary tangles, both of which are neurotoxic and 
contribute to progressive neurodegeneration.  The role of apoE in these events is unclear, 
although it co-localizes with amyloid-rich neuritic plaques in AD brains [15,16] and 
accumulates in regions of damaged or regenerating nerves, perhaps to scavenge and return 
released cholesterol for axonal regeneration [17].  Studies in vitro and in transgenic mouse 
models [18] underline extensive roles for apoE in neurobiology and also reveal isoform 
differences.  In some cases apoE3 fulfills protective functions, in a manner that apoE4 cannot; 
for example, in binding and stabilising microtubules to inhibit hyperphosphorylation of tau 
[14,18-20], and in promoting neurite extension which apoE4 impedes [21,22].  In others, apoE4   4
is neurotoxic, for example by forming stable complexes with Aβ [15,16] or enhancing 
fibrillization of Aβ peptides to generate neuritic plaques [18].  
In the brain, nitric oxide (NO) is a ubiquitous intercellular messenger that can modulate 
cerebral blood flow, thrombosis and neurotransmitter release as well as contributing to 
morphogenesis and synaptic plasticity [23,24].  In excess, however, it is volatile and reacts 
rapidly with superoxide to form peroxynitrite, a potential mediator of cyto- and neurotoxicity by 
nitration of amino acids and oxidation of lipids, proteins and DNA [25,26].  We have previously 
shown in platelets [27] and endothelial cells [28] that binding of apoE by one of its receptors, 
apoE receptor 2 (apoER2), can initiate a signalling cascade which upregulates endothelial nitric 
oxide synthase (NOS3) activity and NO production.  Furthermore, this effect is isoform-
dependent with apoE4 releasing much less NO than apoE3 [29]. 
We hypothesise that apoE will also stimulate NO biosynthesis in neuronal cells and that 
apoE4 will generate inappropriate amounts compared to apoE3.  As a prelude, we have 
quantified mRNA transcripts of lipoprotein receptors that bind apoE, including apoER2 and 
scavenger receptor class B, types I and II (SR-BI and SR-BII), using real-time PCR and a 
diverse panel of human cells, as well as neuronal and astrocytic cell lines.  Expression of the 
three NOS isoenzymes and Akt, the NOS3 regulatory kinase, were also studied.   We found that 
brain cells had the highest levels of apoER2 mRNA and intriguingly that SR-BII predominated 
over the more common splice variant, SR-BI. The findings also identified suitable cell lines for 
investigating apoE-dependent biosynthesis of NO in the brain: H4 neuroglioma, IMR-32 
neuroblastoma, SH-SY-5Y neuroblastoma and CCF-STTG1 astrocytoma cells. 
 
2. Materials and Methods 
 
2.1 Optimization of PCR conditions 
Prior to quantitative assays, PCR primers and conditions were established by standard PCR 
using DNA templates from CCF-STTG1 astrocytoma and SH-SY-5Y neuroblastoma cells.   
These were cultured in RPMI 1640 and Dulbecco’s modified Eagle’s media (Sigma), 
respectively, supplemented with 10% fetal calf serum and 2mM glutamine (both Life 
Technologies), at 37°C in a 5% CO2 saturated incubator.  Cells were passaged when 70-80% 
confluent (usually 2-3 times a week) and DNA was extracted using a commercial kit (Qiagen 
DNeasy).  For RNA preparation, cells were lysed with TRIzol (Life Technologies), extracted 
with phenol-chloroform and the isolated RNA dissolved in 0.1% diethyl pyrocarbonate (DEPC)   5
water for cDNA synthesis.  Reverse transcription was accomplished with oligo-(dT) primers, a 
mix of dNTPs and the reverse transcriptase enzyme (BioScript, BioGene).  
PCR primers were designed using GeneFisher (http://bibiserv.techfak.uni-bielefeld.de/ 
genefisher/), based on the complete mRNA coding sequences of target genes (GenBank; Table 
1), to generate amplicons between 100-200bp; this ensures maximum PCR efficiency when 
detecting with the intercalating fluorogenic dye, SYBR Green I.  Tubes contained 10x PCR 
buffer (2.5µl), 50mM MgCl2 (1µl), Taq polymerase (0.125µl; Invitrogen), 10mM dNTP 
(0.125µl) mix, 10mM forward and reverse primers (each 1µl), 200ng/µl cDNA (2µl), and water 
(17.25µl) and reactions were performed in a standard thermocycler (Biometra TRIO-
thermoblock), running the program: 94ºC for 5 min, 45 cycles of 94ºC for 20 s, 60ºC for 30 s, 
72ºC for 30 s, and a hold of 72ºC for 10 min.  PCR products were visualised under ultra-violet 
light, following electrophoresis on 2% agarose gels containing 0.01% ethidium bromide. 
 
2.2 Preparation of TaqCell plates 
Analysis of gene expression was performed using a human cell line and primary cell 
'TaqCell’ masterplate.  Briefly, total RNA was extracted from 38 cell lines, including two 
neuroblastoma cell lines, IMR-32 and SH-SY-5Y, which were also differentiated into more 
neuron-like morphologies with extended neurites (Table 2).  This was achieved by treating 
IMR-32 cells for 7 days with 1µM retinoic acid, and by supplementing SH-SY-5Y growth 
medium for 7 days with 1mM dibutryl cAMP, 100ng/ml 2.5S nerve growth factor, 10µg/ml 
gangliosides, and 0.5µM sodium butyrate.  Each RNA (50µg) was reverse transcribed using 
oligo-(dT) 12-18 and SuperScript II reverse transcriptase (Life Technologies) and the cDNA 
diluted into 96-well plates.  The plates with wells containing 5µl of cDNA reverse transcribed 
from 50ng total RNA from the different cells were then stored at -80ºC until use. 
 
2.3 Quantitative RT-PCR on TaqCell plates 
To each well of cDNA template (5µl), a 20µl reaction mix was added containing 12.5µl 
‘2x PCR mastermix’ (comprising optimal amounts of SYBR Green I, MgCl2, dNTP and Taq 
polymerase), 1µl of 10µM forward primer, 1µl of 10µM reverse primer, and 5.5µl water.  PCR 
assays were performed in duplicate on an ABI 7700 Sequence Detection system (Applied 
Biosystems) running the cycling conditions: 50ºC for 2 min, 95ºC for 10 min, 45 cycles of 95ºC 
for 15 s, and 60ºC for 1 min.  Immediately following this reaction, melt curve analysis was 
performed by heating the plate from 60ºC to 99ºC and measuring SYBR Green I dissociation 
from the amplicons.  This allowed determination of reaction specificity where a single peak in a   6
first derivative plot was indicative of a single amplification product, whereas multiple peaks 
implied co-amplification of several cDNA species.  The copy number of mRNA-derived cDNA 
in each sample was calculated from a standard curve generated with the use of known amounts 
of plasmid or genomic DNA.  Housekeeping genes, β-actin and GAPDH, were measured for 
reference to verify that all samples were integral and of comparable quality.  Genomic DNA 
contamination of the original RNA samples was negligible (<10 copies genomic DNA/50ng 
RNA), as shown by TaqMan assay of genomic sequence for 10 genes in replicate samples taken 
through the reverse transcription procedure, but with the reverse transcriptase omitted.  
 
3. Results 
 
3.1 Standard PCR assay to test primers 
Before primers were used in TaqCell plate assays, it was important to verify that each 
chosen pair would selectively amplify their target under identical conditions.  This was done 
using cDNA templates from CCF-STTG1 and SH-SY-5Y cells and performing reactions in a 
standard thermocycler, in some cases evaluating several primer pairs for each target.  The final 
ones selected all showed clear, single-band products by electrophoretic gel analysis for each 
lipoprotein receptor (Fig. 1A), and also for the NOS isoforms and PKB/Akt (Fig. 1B), without 
obvious contamination by artefactual bands, mispriming, or primer-dimer complexes.  A 
reaction using validated TaqCell  primers for the housekeeping gene, β-actin, as a positive 
control, also gave a single band (Fig, 1B).  
 
3.2 Expression of LDL-receptor family members 
Expression of the low-density lipoprotein receptor (LDL-r) was observed in all cell lines 
(Fig. 2A).  With few exceptions, copies of mRNA detected exceeded 100,000/50ng total RNA 
across the whole plate, with UT7-Epo cells having the highest level.  Expression levels in the 
brain-derived cells did not obviously differ from the other cell lines.  The VLDL-r showed a 
distinct expression profile (Fig. 2B), with large differences in mRNA levels between cell types.  
The highest levels of gene expression were generally in cells from the vessel wall, while brain-
derived cells also displayed strong expression, both in astrocytoma and neuroblastoma cells.  In 
the two differentiated neuroblastoma cells, expression of the VLDL-r was upregulated, 2.9-
times in IMR-32 and 1.5-times in SH-SY-5Y.  Similar upregulation was also seen in AOSMC 
smooth muscle cells (2.9-times higher) following serum stimulation.   7
Although all cell lines expressed LRP, mRNA levels across the TaqCell plate were highly 
cell-dependent, with vessel wall-derived cell lines and macrophages giving the highest copy 
numbers (Fig. 2C).  As with VLDL-r expression, there was upregulation of LRP in the 
differentiated brain-derived cell lines, markedly so for IMR-32 cells (32-times), while 
expression in SH-SY-5Y cells doubled.  ApoER2 mRNA was detected at a lower level than the 
other LDL-r gene family members (Fig. 2D).  However, a survey across the plate revealed that 
both astrocytoma and neuroblastoma cell lines displayed high apoER2 expression, relative to the 
other cell types, with the greatest level found in H4 neuroglioma cells.  Differentiated IMR-32 
cells showed a 30% rise in apoER2 mRNA, consistent with increased expression of LDL-r and 
VLDL-r, whereas this was not seen in SH-SY-5Y cells, which expressed 55% less apoER2 
mRNA than undifferentiated cells.  
 
3.3 Expression of HDL receptors, SR-BI and SR-BII 
Expression of the high-density lipoprotein (HDL) receptors, SR-BI (Fig. 3A) and SR-BII 
(Fig. 3B) was readily apparent in nearly all cell types on the TaqCell plate. For SR-BI, the level 
of mRNA was generally much higher in the astrocytoma cell lines than in the neuroblastoma 
lines, although H4 neuroglioma cells were an exception.  This preferential expression in 
astrocytoma lines was less obvious when levels of SR-BII mRNA were analysed, as IMR-32, 
SH-SY-5Y and NT-2 neuroblastoma cells showed strong expression.  SR-BII, the splice variant 
of SR-BI, is produced by exon-skipping to give a mRNA transcript that differs by 129bp.  The 
frequency of such an event is rare, making SR-BI the predominantly expressed variant. This is 
consistent with our TaqCell data, which reveal greater expression of SR-BI than SR-BII in 
virtually all non-brain cell lines.  Interestingly, in many brain-derived cells SR-BII 
predominated as clearly shown when the SR-BII:SR-BI ratio was calculated (Fig. 3C).   
However, this preferential expression of SR-BII was confined to neuroblastoma cells, as each of 
the four astrocytoma cell lines had higher copy numbers of SR-BI mRNA than SR-BII mRNA.  
In three cells, differentiated IMR-32, SK-N-SH and NT-2 precursor cells, there was over 30-
times greater expression of SR-BII than SR-BI.  These findings contrast with previous reports of 
the proportional distribution of these receptors in other tissues [30], and with our present survey 
across a wide range of cell types.  
 
3.4 Expression of NOS isoforms and PKB/Akt 
The three NOS isoform mRNAs were detected at lower levels than those of the lipoprotein 
receptors, rarely exceeding 4,000 mRNA copies detected/50ng total RNA.  NOS1 mRNA was   8
detected at the lowest level with several of the brain-derived cell lines showing no expression 
(Fig. 4A).  SH-SY-5Y cells gave the highest level of 430 mRNA copies detected (and was also 
highest across the whole plate; data not shown), although upon differentiation there was a 
dramatic decrease in NOS1 mRNA expression.  NOS2 mRNA was detected in all the brain-
derived cells with half showing a ‘basal’ expression level of ~400 mRNA copies detected/ 50ng 
total RNA (Fig. 4B), which was similar to that detected in the other cell types on the plate (data 
not shown).  NOS3 mRNA was also readily detected and ten of the twelve brain-derived cells 
gave a consistent expression level of 1500-3000 mRNA copies detected/ 50ng total RNA.  The 
two exceptions, C13 and differentiated IMR-32 cells, gave levels of 4,200 and 8,000 mRNA 
copies detected/ 50ng total RNA, respectively (Fig. 4C).  For both NOS2 and NOS3, the two 
differentiated cell lines showed similar changes in mRNA expression compared to their 
undifferentiated counterparts.  In the case of IMR-32 cells differentiation produced 3-4-fold 
increases in NOS2 and NOS3 expression, while in SH-SY-5Y cells the change was in the 
opposite direction with differentiation leading to halving of mRNA copy numbers (Fig. 4B,C).   
Expression of Akt mRNA (Fig. 4D) was usually high across all cell types on the TaqCell 
plate, many cell lines having an expression level fluctuating marginally around the mean of 
100,000 mRNA copies detected/ 50ng total RNA.  Most brain-derived cells also showed good 
expression of Akt mRNA, with values similar to other cell lines and in some cases exceeding 
them. The three highest expressing lines were the 1321N1, C13 and CCF-STG1 astrocytoma 
cells, which each gave levels of ~120,000 mRNA copies detected/ 50ng total RNA.   
Differentiation of IMR-32 and SH-SY-5Y cell lines produced 170% and 40% increases in 
expression, respectively, to about 80,000 mRNA copies detected/ 50ng total RNA compared to 
the undifferentiated forms.  
 
4. Discussion 
 
This study has used quantitative RT-PCR to measure mRNA expression levels of a range 
of genes involved in apoE metabolism and NO biosynthesis, focusing on genes encoding 
receptors capable of binding apoE-containing lipoproteins.  To our knowledge, this is the first 
such survey of gene expression, covering an extensive and diverse range of human tissue cell 
lines, including those derived from brain-cells.  The generic probe, SYBR Green I, which 
intercalates into the double-strand DNA amplicons, was used to monitor PCR reactions rather 
than a synthetic oligonucleotide-based reagent specific for each gene.  However, all assays were 
sensitive and specific, as judged by rigorous electrophoretic and melt curve analyses of primer 
pairs prior to their use in TaqCell plates.  Nevertheless, individual assays give only information   9
on mRNA levels; in particular, whether a gene is expressed by a cell line, and its copy number 
relative to other cell lines and to other genes investigated.  It does not follow, however, that 
mRNA levels are a true reflection of protein expression; an important consideration when 
evaluating the data and for future studies.  
The LDL-r is the archetypical cell-surface receptor mediating endocytosis of its ligand, in 
this case apoE or apoB100 which deliver lipid nutrients.  It is expressed in virtually all cells and 
tissues at variable levels, which our findings in TaqCell plates confirm.  The LDL-r is widely 
expressed in brain and, as apoB100 and LDL are absent from cerebrospinal fluid [31], it appears 
that their role in lipid transport and cholesterol homeostasis is fulfilled by apoE [17,31].   
Structurally, the VLDL-r and apoER2 are very similar to the LDL-r and to each other; both bind 
apoE3 and apoE4 with similar affinities [32,33].  The VLDL-r is abundantly expressed in heart 
and skeletal muscle and adipose, which all actively metabolize fatty acids acquired from 
triglyceride-rich lipoproteins [34,35], whereas apoER2 is absent from these tissues and reported 
to predominate in brain, with a widespread distribution [36].  Subsequent immunohistochemical 
studies also revealed VLDL-r expression in brain, including hippocampal cortical neurons and 
microglia, particularly those associated with senile plaques [37,38].  Data from our TaqCell 
plates were consistent with this tissue distribution, including the strong expression of VLDL-r 
and apoER2 across most of the brain-derived cell lines.   
Studies in mice that lack both VLDL-r and apoER2 have highlighted key roles for these 
receptors in neuronal migration and development of the nervous system.  The double knockout 
mice have marked behavioural and neuroanatomical features, which includes cerebellar 
dysplasia and severe ataxia, and disruption of cortical layering.  This phenotype is identical to 
the mutant mouse strains, Scrambler  and  Reeler, which have dysfunctional forms of the 
intracellular adaptor protein, Disabled-1 (Dab-1) [39], and the large secreted signalling 
glycoprotein, Reelin [39,40], respectively.  Genetic and biochemical studies now group these 
disparate proteins into a common signalling pathway in which Reelin binds with high-affinity to 
VLDL-r or apoER2, an interaction which promotes Dab-1 binding to the cytoplasmic NPxY 
motifs of both receptors [14].  This initial Reelin signal stimulates tyrosine phosphorylation of 
Dab-1, which in turn can then activate a variety of downstream signalling components 
[14,41,42].  
At 600-kDa, LRP is much larger than the other LDL-r family members studied and 
contains two NPxY motifs and one tyrosine-based YxxL motif.  It has broad binding specificity 
with over 30 different ligands many of which are internalized, interestingly via the alternative 
endocytic signalling motif, YxxL, which dominates [43].  In addition,  several adaptor and 
scaffold proteins, including Dab-1, potentially bind the cytoplasmic NPxY motifs of LRP and,   10
although biochemical and physiological details are incomplete, numerous regulatory functions 
are suggested, including mitogen-activated protein (MAP) kinase signalling, ion channel 
function, microtubular transport, and axon guidance [41,44,45].  Genetic association studies 
suggest a direct link between LRP and AD, as the C766T polymorphism in exon 3 of LRP is 
under-represented [46].  However, although brains of AD patients with CT or TT genotypes 
contain higher levels of LRP [47] and circumstantial evidence suggests that LRP promotes Aß
 
clearance [48], the relationship remains controversial [49].  Similarly, polymorphisms in the 
VLDL-r [37,38] and apoER2 [50] have been identified and are suggested to be risk factors for 
AD, but further studies are needed to verify these possibilities.  
Scavenger receptor class B, type I mediates the selective uptake of cholesteryl esters from 
HDL without degrading the particles.  It was the first authentic HDL binding protein to be 
characterized [51], although other ligands including apoE are now recognized [52].  A splice 
variant, termed SR-BII, was subsequently identified; this results from exon 12 skipping [30,53] 
to produce a receptor with a different C-terminal cytoplasmic tail, but identical extracellular 
binding region, to that of SR-BI.  This implies differential functions; for example, the interaction 
between C-terminal SR-BI and PDZK1, a scaffolding protein [54], would not occur with SR-
BII.  On the other hand, cytoplasmic SR-BII contains six PxxP motifs, two being conserved in 
rat, mouse and hamster, which are potential ligands for tyrosine kinases or adaptor proteins with 
Src homology 3 (SH3) domains [30].  The presence of these motifs, which are also seen in 
cytoplasmic apoER2 [55], suggests that SR-BII may initiate signalling pathways that cannot be 
mediated by SR-BI; an exciting possibility given the preferential expression of SR-BII in many 
brain-derived cell lines (Fig. 3C).  
Copy numbers of NOS mRNA transcripts were generally low in all cells, although 
presumably adequate to maintain basal NO levels that are biologically functional without being 
cyto- or neurotoxic.  Under normal physiological conditions, relatively little NO is synthesized 
and it appears that cells only transcribe NOS genes at low levels.  Indeed, production of NO 
commonly reflects the catalytic activity of the enzyme, which depends on intracellular Ca
2+ 
concentrations, the availability of substrates or co-factors, and an array of heterologous protein 
partners [56].  Both NOS1 and NOS3 are constitutively transcribed, whereas NOS2 expression 
is induced by cytokines, such as IFN-γ.  Recently, phosphorylation at Ser
1177 has emerged as a 
key regulatory mechanism of NOS3 activity, most likely because the enzyme can then bind 
calcium-activated calmodulin at low calcium concentration.  The phosphorylation of NOS3 can 
be mediated by protein kinase A (PKA) or AMP kinase, but is accomplished more frequently by 
protein kinase B (PKB; usually termed Akt), which also helps regulate apoptosis and cellular 
proliferation and is itself phosphorylated and activated by phosphatidylinositol (PI) 3-kinase   11
[57].  Here, we have measured NOS and Akt mRNA transcripts in each cell line, which as 
discussed above may not accurately reflect protein levels.  Thus, although our data identify cells 
that express the three isoenzymes and the key activator of NOS3, the measurement of NOS 
proteins and a functional assessment of NO synthesis must await additional investigations.   
In summary, our study has demonstrated that receptors recognizing apoE are widely 
expressed in brain-derived cell lines.  Of note were the strong expression of apoER2 in these 
cells, which we have previously implicated in apoE-mediated stimulation of NO release in 
platelets and endothelium, and the preferential expression of SR-BII, which is rich in 
cytoplasmic SH3 motifs, over the normal splice variant, SR-BI.   Our findings also identified H4 
neuroglioma, IMR-32 neuroblastoma, SH-SY-5Y neuroblastoma and CCF-STTG1 astrocytoma 
cells as being suitable human brain cells for investigating apoE-dependent biosynthesis of NO 
and whether apoE4 and apoE3 have differential effects.  
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Table 1  
Primer sequences selected for TaqCell plate assays and the expected PCR product sizes. 
 
Gene 
GenBank 
accession 
number 
Primer  Sequence 5’ – 3’  Product 
size 
Forward  GCGAAGATGCGAAGATATCGATG 
LDL-r NM00527 
Reverse  CCGGTTGGTGAAGAAGAGGTAG  172bp 
        
Forward  CTGCAGCCATTGCTGTTGATTGG 
VLDL-r NM003383  Reverse  CCAGTAAACAAAGCCAGACAGTG  173bp 
        
Forward  GATCCCAATGACAAGTCAGATGC 
LRP NM002332  Reverse  ATGCCATTGGTCACCACGTCTTC  173bp 
        
Forward  GCGGAACTATTCACGCCTCA 
ApoER2 D50678 Reverse  TGCGATTGGTGGCAACTTC  74bp 
        
Forward  GGTCCCTGTCATCTGCCAA 
SR-BI Z22555  Reverse  CTCCTTATCCTTTGAGCCCTTT  85bp 
        
Forward  TCCTGAGGACACCGTGAGC 
SR-BII Z22555  Reverse  GAGGCTCAGGCTGTGG  123bp 
        
Forward  TGCTGCGATGCAATGCTT 
NOS1 AH005382  Reverse  GACGGCCATGTTCCAGT  117bp 
        
Forward  ACAAGCCTACCCCTCCAGAT 
NOS2 NM153292  Reverse  CCTGGCCAGATGTTCCTCTA  104bp 
        
Forward  CCTGGAGAATGAGCAGAAGG 
NOS3 A519768  Reverse  GTTGACCATCTCCTGATGGAA  109bp 
        
Forward  TCACTGCGCTGAAGTATGCCTTC 
PKB/Akt M95936 Reverse  CGCGAGTGCAAGTACTCAAGAG  171bp 
        
Forward  AGGCTACGAGCTGCCTGACG 
β-Actin  X00351  Reverse  GTAGTTTCGTGGATGCCACAGGACT  215bp 
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Table 2  
Human primary cells and cell lines present on the TaqCell plate. Brain-derived cell lines are 
highlighted. 
 
 
Cells, Cell Lines and Tissue Source 
 
 
Description 
 
Vessel Wall   
   AOSMC- (unstimulated)  Aortic smooth muscle cells 
   AOSMC+ (serum stimulated)  Aortic smooth muscle cells 
   HCAEC  Human coronary artery endothelial cells 
   HCA-SMC  Human coronary artery smooth muscle cells 
   Bladder-SMC  Bladder smooth muscle cells 
  
Liver   
   Chang  Liver cells 
   HepG2  Hepatocyte carcinoma 
   WRL68  Liver carcinoma 
  
Blood   
   Lymphocytes  Primary culture 
   Macrophages (monocyte-derived)  Primary culture 
   THP-1 (unstimulated)  Monocytic 
   Neutrophils  Primary culture 
   CMK-86  Megakaryocyte 
   M-07e  Megakaryocyte 
   UT7-Epo  Megakaryocyte 
  
Bone/Cartilage   
   C20A4  Chondrocytes 
   HOS  Osteosarcoma cells 
   MG63  Osteosarcoma cells 
   SAOS2  Osteosarcoma cells 
   HAC60  Articular chondrocytes 
  
Astrocytoma/glia   
   1321N1  Brain astrocytoma 
   C13  Immortalised immature microglial cell 
   Hs-683  Glioma 
   CCF-STTG1  Astrocytoma 
   
Neuroblastoma   
   H4  Brain neuroglioma 
   IMR32- NCA240  Neuroblastoma 
   IMR32+ NCA240  Neuroblastoma 
   SK-N-MC  Neuroblastoma 
   SK-N-SH  Neuroblastoma 
   SH-SY-5Y- (undifferentiated)  Neuroblastoma 
   SH-SY-5Y+ (differentiated)  Neuroblastoma 
   NT-2 precursor cells  Ntera/D1 cell line, derived from a human teratocarcinoma, represents a 
committed neuronal precursor stage of differentiation 
  
Others   
   Prostate SMC  Prostate smooth muscle cells, primary, p3 
   HK-2  Kidney, cortex, proximal tube, HPV-16 transformed 
  
Parental Background Cells   
   HEK 293  Embryonic kidney 
   HeLa  Epithelilial cervical adenocarcinoma 
   COS-1  Kidney fibroblast-like, derived from CV-1 cells, transformed with origin-
defective mutant of SV-40 coding for WT T-antigen 
   MRC-9  Foetal lung fibroblast (female) 
   18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. PCR products of genes investigated. (A) Lipoprotein receptors – LDL-r, VLDL-r, LRP, 
apoER2, SR-BI, and SR-BII. (B) Proteins involved in NO biosynthesis  – NOS1, NOS2, NOS3, 
and PKB/Akt. Reactions were performed in a standard thermocycler and the products separated 
by 2% agarose gel electrophoresis. 
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Fig. 2. Expression of LDL-receptor gene family members by TaqCell plate assay.  Levels of 
mRNA  were measured in 38 human cell lines and primary cells for (A) LDL-r, (B) VLDL-r, 
(C) LRP and (D) apoER2.  Brain-derived cell lines are highlighted.  Data  shown are the mean 
of a duplicate measurement (± S.E.) of mRNA copy numbers in 50ng of reverse transcribed total 
RNA from the same batch of cells.  Note that the scaling on the Y-axis of each graph differs. 
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Fig. 3.  Expression of HDL receptors by TaqCell plate assay.  Levels of mRNA were measured 
in 38 human cell lines and primary cells for (A) SR-BI and (B) SR-BII.  Data shown are the 
mean of a duplicate measurement (± S.E.) of mRNA copy numbers in 50ng of reverse 
transcribed total RNA from the same batch of cells.  (C) Calculated ratio of SR-BII:SR-BI 
mRNA expression.  Brain-derived cell lines are highlighted; five lines gave ratios greater than 
2.0, in four cases markedly so, and the individual values for these are shown above the bars. 
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Fig. 4.  Expression of NOS isoforms and PKB/Akt by TaqCell plate assay.  Levels of mRNA 
were measured in 38 human cell lines and primary cells for (A) NOS1, (B) NOS2, (C) NOS3 
and (D) the NOS3 regulatory kinase, PKB/Akt.  Results are shown only for the brain-derived 
cells and are the mean of a duplicate measurement (± S.E.) of mRNA copy numbers in 50ng of 
reverse transcribed total RNA from the same batch of cells. Note that the scaling on the Y-axis 
of each graph differs. 
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